On 23 September, the Swiss-based biopharmaceutical company AC Immune announced that its partner Genentech, a member of the Roche group, has reported top line results from a Phase II clinical trial of semorinemab, an anti-tau monoclonal antibody, in early Alzheimer’s disease (AD). Unfortunately the results show that the study did not meet its primary efficacy endpoint.
Alzheimer Europe’s 
Ahead of debates in the European Parliament on EU4Health, the EU’s forthcoming standalone health programme, the EU4Health Civil Society Alliance has published a position statement outlining key principles and points which must underpin the future Health Programme.
Two Vice-chairs of the European Alzheimer’s Alliance (EAA), submitted written questions to the Commission this month. They asked about the place of dementia in the forthcoming European Disability Strategy, and in the future research priorities of the EU. The EAA has also gained a new member, Chrysoula Zacharopoulou MEP.
Congratulations to our members for all their hard work this World Alzheimer’s Day. The pandemic has put up so many roadblocks, but our members found new and creative ways to carry out their all-important awareness-raising and fundraising activities.
The 30th Alzheimer Europe Conference (#30AEC) is fast-approaching, with only three weeks to go! The conference will take place online for the first time, from 20-22 October, and registrations will close on 19 October. Conference registration gives you admission to all sessions, access to poster presentations, to chat rooms and to all conference videos after the event.
This newsletter received funding under an operating grant from the European Union’s Health Programme (2014-2020).